A Study of an Investigational V212/Heat-Treated Varicella-Zoster Virus (VZV) Vaccine in Immunocompromised Adults (V212-002)

Not Recruiting

Trial ID: NCT00535236


This study will evaluate the safety and immunogenicity of a heat-treated VZV vaccine in autologous or allogeneic hematopoietic cell transplant (HCT) recipients, human immunodeficiency virus (HIV)-infected participants with a baseline cluster of differentiation 4 (CD4) cell count ≤200 cells/mm^3, participants with solid tumor malignancy (STM; breast, colorectal, lung, or ovarian malignancies) receiving chemotherapy, and participants with hematologic malignancy (HM; leukemia or leukemia-like disease, lymphoma or lymphoma-like disease, or multiple myeloma). The primary hypothesis is that the heat-treated VZV vaccine will elicit significant VZV-specific immune responses measured by either glycoprotein-based enzyme-linked immunosorbent assay (gpELISA) or VZV gamma interferon enzyme-linked immunospot (IFN-ELISPOT) at 28 days post dose vaccination 4 in, HIV-infected participants, participants with STM, and participants with HM. The primary immunogenicity objective and endpoints were considered by the protocol as exploratory for the autologous and allogeneic HCT groups.

Official Title

A Phase I, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of V212/Heat-Treated Varicella-Zoster Virus (VZV) Vaccine in Immunocompromised Adults

Stanford Investigator(s)

Wes (Janice) Brown
Wes (Janice) Brown

Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

Dora Ho
Dora Ho

Clinical Professor, Medicine - Infectious Diseases


Inclusion Criteria:

   - Men and women > or = to 18 years of age who are scheduled to receive an autologous or
   allogeneic hematopoietic cell transplant within 60 days of enrollment

   - HIV-infected participants with a baseline CD4 cell count < or = to 200 cells/mm^3

   - Participants with hematologic malignancies; or participants who are receiving
   chemotherapy for breast, colorectal, lung, or ovarian malignancies

Exclusion Criteria:

   - History of allergy to any vaccine component

   - Prior history of HZ

   - Prior history of receipt of any varicella or zoster vaccine


biological: V212

biological: Placebo

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Dora Ho